摘要
目的应用瞬时弹性成像技术(FibroScan)对非酒精性单纯性脂肪肝(NAFL)患者肝脏硬度(E)及受控衰减系数(CAPTM)进行检测及分析。方法选取NAFL患者729例及正常健康人300例,均行腹部超声检查、实验室检查及FibroScan测量E及CAPTM值。结果 NAFL组临床资料各项数值均高于对照组(P<0.01),E值与丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、CAP呈正相关(P<0.05),与总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)呈负相关(P<0.01),CAPTM值三酰甘油(TG)、空腹血糖(FPG)、高密度脂蛋白胆固醇(HDL-C)、硬度值(E)呈正相关(P<0.05)。不同人群特征对失败率存在影响:失败率随BMI升高而升高,老年人测量失败率高于年轻人,女性失败率高于男性,肋间隙狭窄者失败率高(P均<0.01)。结论 FibroScan是目前唯一完全无创、无痛、对肝脏无损伤的评估与监测脂肪肝的量化工具,对脂肪定量具有较高的敏感度和准确度,对脂肪肝的诊断及定期跟踪随访具有较高的价值。
Objective Using transient elastography （ FibroScan ） to detect liver stiffness （ E ） and controlled attenuation coefficient （ CAPTM ） in patients with nonalcoholic fatty liver （ NAFL ） , and to explore the correlation between FibroScan value and metabolic parameters .Methods The 729 patients with NAFL （ NAFL group ） and 300 healthy subjects （ control group ） received abdominal ultrasound examination , laboratory examination and FibroScan measurement for E and CAPTM value .Results The clinical parameters in NAFL group were significantly higher than those in control group （ P 〈0.01）.The E value in NAFL group was positively correlated to alanine aminotransferase （ALT）,aspartate aminotransferase （AST）, CAP, however, which was negatively correlated with total cholesterol （ TC）, high density lipoprotein cholesterol （HDL-C）（ P 〈0.01）.CAPTM value was positively correlated to triglycerides （TG）,fasting blood glucose （FPG）,high density lipoprotein cholesterol（HDL-C）,hardness（E）（ P 〈0.05）.The characteristics in different population had impact on failure rate,failure rate was increased with the increase of BMI ,moreover,the measurement failure rate in the elderly was higher than that in young people ,which in females was higher than that in males ,especially the patients with intercostal space narrow had higher failure rate （ P 〈0.01）.Conclusion FibroScan is currently the only completely non-invasive, painless quantitative tools to evaluate and monitor fatty liver ,without damage to liver ,which has higher sensitivity and accuracy ,and has important value in the diagnosis and regular follow-up in patients with fatty liver .
出处
《河北医药》
CAS
2014年第11期1611-1614,共4页
Hebei Medical Journal
